IL250334B - Flagellin compounds and their uses - Google Patents

Flagellin compounds and their uses

Info

Publication number
IL250334B
IL250334B IL250334A IL25033417A IL250334B IL 250334 B IL250334 B IL 250334B IL 250334 A IL250334 A IL 250334A IL 25033417 A IL25033417 A IL 25033417A IL 250334 B IL250334 B IL 250334B
Authority
IL
Israel
Prior art keywords
compositons
flagellin
flagellin compositons
Prior art date
Application number
IL250334A
Other languages
English (en)
Hebrew (he)
Other versions
IL250334A0 (en
Original Assignee
Cleveland Biolabs Inc
Genome Prot Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Biolabs Inc, Genome Prot Inc filed Critical Cleveland Biolabs Inc
Publication of IL250334A0 publication Critical patent/IL250334A0/en
Publication of IL250334B publication Critical patent/IL250334B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL250334A 2014-07-30 2017-01-29 Flagellin compounds and their uses IL250334B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462031116P 2014-07-30 2014-07-30
US201562110744P 2015-02-02 2015-02-02
US201562117366P 2015-02-17 2015-02-17
PCT/US2015/042684 WO2016019034A1 (en) 2014-07-30 2015-07-29 Flagellin compositons and uses

Publications (2)

Publication Number Publication Date
IL250334A0 IL250334A0 (en) 2017-03-30
IL250334B true IL250334B (en) 2021-09-30

Family

ID=55218277

Family Applications (2)

Application Number Title Priority Date Filing Date
IL250334A IL250334B (en) 2014-07-30 2017-01-29 Flagellin compounds and their uses
IL250331A IL250331B (en) 2014-07-30 2017-01-29 Flagellin-based agents and uses including effective vaccination

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL250331A IL250331B (en) 2014-07-30 2017-01-29 Flagellin-based agents and uses including effective vaccination

Country Status (14)

Country Link
US (9) US10202426B2 (enExample)
EP (2) EP3174893B1 (enExample)
JP (3) JP6940916B2 (enExample)
KR (1) KR20170031251A (enExample)
CN (2) CN107087411B (enExample)
AU (2) AU2015296555B2 (enExample)
BR (1) BR112017001796A2 (enExample)
CA (2) CA2994218A1 (enExample)
EA (2) EA035372B1 (enExample)
ES (1) ES2816630T3 (enExample)
IL (2) IL250334B (enExample)
MX (2) MX385845B (enExample)
WO (2) WO2016019034A1 (enExample)
ZA (1) ZA201701286B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170031251A (ko) * 2014-07-30 2017-03-20 클리브랜드 바이오랩스, 아이엔씨. 플라젤린 조성물 및 용도
US11058758B2 (en) 2014-11-20 2021-07-13 National Institutes Of Biomedical Innovation, Health And Nutrition TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same
UY37816A (es) 2017-07-20 2019-02-28 Spogen Biotech Inc Polipéptidos bioactivos para mejorar la protección, crecimiento y productividad en plantas
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
WO2019094528A1 (en) * 2017-11-09 2019-05-16 The Scripps Research Institute An improved heroin vaccine
JP7037930B2 (ja) * 2017-12-19 2022-03-17 株式会社小糸製作所 車両の運転支援装置、命令表示装置及び車両用灯具。
CN109879940A (zh) * 2017-12-25 2019-06-14 苏州和锐生物科技有限公司 鞭毛g多肽、抗体捕获器件及试剂盒
EA202092530A1 (ru) * 2018-04-24 2021-02-01 Джиноум Протекшн, Инк. Способы облегчения старческой астении и старения
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
WO2020118192A1 (en) * 2018-12-07 2020-06-11 Genome Protection, Inc. Engineered flagellin-derived compositions and uses
CN111718417B (zh) * 2019-03-19 2022-10-14 宁波鲲鹏生物科技有限公司 含有荧光蛋白片段的融合蛋白及其用途
KR102169663B1 (ko) * 2019-03-28 2020-10-26 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물
KR20220009955A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료
CN110157655B (zh) * 2019-05-22 2021-06-01 中国兽医药品监察所 一种无毒性气肿疽梭菌基因工程亚单位疫苗用菌种及其应用
CN114502573A (zh) * 2019-08-30 2022-05-13 基因组保护股份有限公司 提高疫苗功效的方法
CN118754841A (zh) 2020-05-19 2024-10-11 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
KR102720967B1 (ko) * 2020-06-04 2024-10-23 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물
TWI746188B (zh) * 2020-09-28 2021-11-11 中山醫學大學 篩選治療腦炎藥物之平台及其方法
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
US20240277801A1 (en) * 2021-06-30 2024-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosol composition for pulmonary delivery of flagellin
KR102483177B1 (ko) * 2021-07-09 2022-12-29 전남대학교산학협력단 탈-면역 플라젤린 및 이를 포함하는 백신 조성물
KR102514849B1 (ko) * 2021-10-28 2023-03-28 전남대학교산학협력단 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
IL317229A (en) * 2022-06-01 2025-01-01 Flag Bio Inc RNA helpers, methods and uses thereof
KR20240022417A (ko) * 2022-08-10 2024-02-20 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
WO2025172452A1 (en) * 2024-02-14 2025-08-21 Institut National de la Santé et de la Recherche Médicale Combination for treating bacterial infection due to pseudomonas aeruginosa antibiotic-resistant strain

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3007812A (en) 1957-02-11 1961-11-07 Allied Chem Water-repellent compositions, method of water-proofing porous surfaces therewith, and resulting water-repellent surfaces
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
ES2070312T5 (es) * 1988-12-19 2003-05-16 American Cyanamid Co Vacuna de proteina de membrana exterior meningococica de clase 1.
ES2088014T3 (es) 1990-09-28 1996-08-01 Sulzer Innotec Ag Aguja hueca para utilizacion medica y procedimiento para la fabricacion de este tipo de agujas huecas.
CA2383007A1 (en) 1992-03-02 1993-09-16 Chiron S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
AU4709401A (en) 1999-11-29 2001-06-12 Inotek Corporation Composition and method for treating a microbial infection
CA2398660A1 (en) 2000-01-31 2001-08-02 Munin Corporation Human cyr61
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2002216500A1 (en) 2000-11-28 2002-06-11 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2003028659A2 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
EP1706133B1 (en) 2003-12-02 2010-10-06 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
US7404963B2 (en) 2004-10-01 2008-07-29 The University Of South Florida Flagellin-based adjuvants and vaccines
EP1824510B1 (en) 2004-12-16 2012-10-31 Wake Forest University Health Sciences Use of flagellin in the immunotherapy of yersinia pestis
EP2460534A1 (en) 2004-12-22 2012-06-06 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
WO2007070623A2 (en) 2005-12-14 2007-06-21 Medistem Laboratories, Inc. Transcatheter tumor immunoembolization
EP2441846A3 (en) 2006-01-09 2012-07-25 The Regents Of the University of California Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
WO2008094275A1 (en) 2007-01-30 2008-08-07 New York University Peptides for treatment of conditions associated with nitric oxide
KR20100034010A (ko) 2007-06-15 2010-03-31 임뮤룩스, 인코포레이티드 Ｔｎｆ­ｒ 효능제 치료 요법의 독성을 경감시키기 위한 ｔｌｒ 효능제 및／또는 타입 1 인터페론의 용도
MX2010001194A (es) 2007-07-31 2010-07-30 Univ Louisiana State Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones.
EA201692127A1 (ru) 2007-11-07 2017-08-31 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческим dec-205
WO2009102818A1 (en) 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Method for reducing the effects of chemotheraphy using flagellin related polypeptides
EP2320948B1 (en) * 2008-08-01 2013-03-06 Cleveland Biolabs, Inc. Methods for treating reperfusion injuries
US8486408B2 (en) * 2008-10-03 2013-07-16 Emory University Methods for the treatment of graft-versus-host disease
BRPI1010937A2 (pt) 2009-05-21 2019-09-24 Astrazeneca Ab composto, uso de um composto, e, método para tratar câncer
NZ598654A (en) 2009-09-02 2014-05-30 Novartis Ag Immunogenic compositions including tlr activity modulators
KR20120104177A (ko) 2009-10-06 2012-09-20 파나셀라 랩스, 아이엔씨. 암을 치료하기 위한 톨 유사 수용체 및 효능제의 용도
CN102892429B (zh) * 2010-03-17 2016-08-31 康奈尔大学 基于被破坏的腺病毒的抗滥用药物疫苗
CN103945863A (zh) * 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
CN102965386A (zh) * 2011-09-02 2013-03-13 中国人民解放军军事医学科学院放射与辐射医学研究所 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法
CN102772795B (zh) * 2012-08-06 2015-07-29 中国人民解放军疾病预防控制所 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用
KR20170031251A (ko) * 2014-07-30 2017-03-20 클리브랜드 바이오랩스, 아이엔씨. 플라젤린 조성물 및 용도

Also Published As

Publication number Publication date
US20200392190A1 (en) 2020-12-17
AU2015296298A1 (en) 2017-03-16
US10669316B2 (en) 2020-06-02
JP2017523180A (ja) 2017-08-17
EA201790273A1 (ru) 2017-07-31
US10202426B2 (en) 2019-02-12
AU2015296555B2 (en) 2020-05-21
US11034733B2 (en) 2021-06-15
AU2015296298B2 (en) 2020-05-21
US20200277339A1 (en) 2020-09-03
EP3174552A4 (en) 2018-02-28
US20210269491A1 (en) 2021-09-02
US10730915B2 (en) 2020-08-04
JP2017523184A (ja) 2017-08-17
EA037407B1 (ru) 2021-03-25
MX385845B (es) 2025-03-18
US10975127B2 (en) 2021-04-13
US20210340190A1 (en) 2021-11-04
BR112017001796A2 (pt) 2018-02-14
CA2994289C (en) 2023-03-14
CN107087411A (zh) 2017-08-22
JP6940916B2 (ja) 2021-09-29
US10336793B2 (en) 2019-07-02
AU2015296555A1 (en) 2017-02-23
CA2994289A1 (en) 2016-02-04
EP3174552B1 (en) 2020-09-16
IL250331B (en) 2021-06-30
EP3174893A4 (en) 2018-01-03
US20180354995A1 (en) 2018-12-13
EP3174893A1 (en) 2017-06-07
MX2017001406A (es) 2017-08-28
JP2021191781A (ja) 2021-12-16
US20170266278A1 (en) 2017-09-21
WO2016019134A8 (en) 2016-03-31
ZA201701286B (en) 2018-04-25
EA035372B1 (ru) 2020-06-03
IL250334A0 (en) 2017-03-30
US20190233478A1 (en) 2019-08-01
MX2017001279A (es) 2017-08-07
EP3174893B1 (en) 2020-05-06
KR20170031251A (ko) 2017-03-20
AU2015296298A8 (en) 2017-03-23
CA2994218A1 (en) 2016-02-04
CN107073092A (zh) 2017-08-18
US11542306B2 (en) 2023-01-03
WO2016019134A1 (en) 2016-02-04
IL250331A0 (en) 2017-03-30
CN107087411B (zh) 2021-06-29
ES2816630T3 (es) 2021-04-05
US20190315810A1 (en) 2019-10-17
EP3174552A1 (en) 2017-06-07
US20180251498A1 (en) 2018-09-06
JP6646039B2 (ja) 2020-02-14
WO2016019034A1 (en) 2016-02-04
EA201790294A1 (ru) 2017-08-31

Similar Documents

Publication Publication Date Title
IL250334B (en) Flagellin compounds and their uses
GB201413355D0 (en) Compositons and methods
IL250568A0 (en) Anti-methanogenic preparations and their uses
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
GB201411197D0 (en) Composition and use thereof
HUE052359T2 (hu) Hidrofluorolefin-bázisú készítmény és alkalmazása
GB201407934D0 (en) Formulation
PL3152226T3 (pl) Modyfikowane cyklopentapeptydy i ich zastosowania
SG11201609490QA (en) Polymer-flavonoid conjugate and uses thereof
IL251059B (en) Arimoclomol formulation
IL248934A0 (en) Topical formulations and their uses
GB201411196D0 (en) Composition and use thereof
PL3184492T3 (pl) Preparat antyseptyczny
GB201407384D0 (en) Formulation
IL248835A0 (en) A preparation of ciritinib
GB201402448D0 (en) Novel formulation
GB201511301D0 (en) Formulation
IL251362A0 (en) formulation
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201412754D0 (en) Formulation
GB201404773D0 (en) Formulation
AP00748S1 (en) Desks
GB201418500D0 (en) Therapeutic compositions